Thursday May 8, 2008
|
|
|
|
|
|
|
|
| 7:30 - 8:30 |
Breakfast & Registration |
|
|
|
|
|
|
| 8:30 - 9:00 |
Welcome: The Global Neurotech Industry 2008 |
|
|
|
|
|
|
|
|
Zack Lynch |
|
|
|
Executive Director, Neurotechnology Industry Organization
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 9:00 - 9:45 |
Investing in Neurotech Panel |
|
|
|
A diverse panel of private, public and strategic investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are the benefits and risks of business models in devices, pharmaceuticals, diagnostics and information technology? What are today's deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries? |
|
|
|
|
|
Jeff Collins |
|
|
Vice President, Pappas Ventures |
|
|
|
|
|
Roger Quy
General Partner, Technology Partners |
|
|
|
|
|
Rajeev Shah
Senior Analyst, RA Capital |
|
|
Kevin Wasserstein
Managing Director, Versant Ventures
Jay Watkins
Managing Director, De Novo Ventures
|
|
|
Moderator: Casey Crawford Lynch |
|
|
Managing Director, NeuroInsights
|
|
|
|
|
| 9:45 - 10:15 |
Networking and Refreshment Break
|
|
|
|
|
| 10:15 - 11:15 |
Addiction, Impulse Control and Obesity |
|
|
Advancing science and acceptance of addiction as a brain disorder are creating opportunities for addressing unmet markets including nicotine, alcohol, and gambling. Treatments for impulse control may also apply to the massive obesity market. |
|
|
|
|
|
Robert Alonso |
|
|
President and CEO, Yaupon Therapeutics |
|
|
|
|
|
Kenneth Chahine
President and CEO, Avigen |
|
|
|
|
|
|
|
|
Mark Knudson |
|
|
President and CEO, Enteromedics |
|
|
|
|
|
Gary Tollefson
President and CEO, Orexigen |
|
|
Session Chair: Selena Bartlett
Director of Preclinical Development Group, Ernest Gallo Clinic and Research Center
|
|
|
| 11:15 - 12:15 |
Drug Delivery and the Blood Brain Barrier |
|
|
The blood brain barrier keeps harmful substances and proteins from damaging the brain, but also prevents therapeutics from reaching their targets. Companies present novel approaches for giving drugs new potential through improved oral delivery and increased blood brain barrier penetration.
|
|
|
|
|
|
|
|
|
|
|
|
Pieter Gaillard
President and CEO, toBBB
Lars Wahlberg
Executive Vice President and COO, NsGene
Erich Mohr
President & CEO, Med-Genesis
Wendye Robbins
President and CEO, Limerick Neuroscience |
|
|
|
|
|
Session Chair: Frank Eeckman |
|
|
NeuroInsights, Centient Biotech |
|
|
|
|
| 12:15 - 1:30 |
Luncheon Keynote
|
|
|
|
|
|
Robert McCooey
Sr. Vice President, Capital Markets Group, NASDAQ
David Ewing Duncan
Commentator and Author
Experimental Man: The State of Neuroscience for the Average Man
|
|
| 1:30 - 2:30 |
Alzheimer's and Cognitive Disorders |
|
|
|
|
|
As the population ages, the market for Alzheimer's and other cognitive disorders is exploding. Current treatments stabilize symptoms only for a short period of time. What is on the horizon for symptom improvement and disease modification from drug and device companies?
|
|
|
|
|
|
Karoly Nikolich
President and CEO, Amnestix
|
|
|
Kees Been
President and CEO, EnVivo Therapeutics |
|
|
Andres Lozano
President and CEO, Functional Neuroscience, Inc.
Cris McReynolds
President and CEO, Satoris Inc.
|
|
|
|
|
|
Session Chair: Roger Quy
General Partner, Technology Partners |
|
|
|
|
|
|
|
| 2:30 - 3:15 |
Paving the Way in New Markets: Case Studies and Panel Discussion |
|
|
|
|
|
Jonathan Kil
President and CEO, Sound Pharmaceuticals
Srinivas Rao
Chief Scientific Officer, Cypress Bioscience
Dan Moore
President and CEO, Cyberonics
Moderator: Casey Crawford Lynch
Managing Director, NeuroInsights
|
|
|
|
|
|
|
|
| 3:15 - 3:45 |
Networking and Refreshment Break |
|
|
|
|
|
| 3:45 - 4:45 |
Insomnia and Sleep Disorders |
|
|
|
|
|
A large late stage pipeline in sleep disorders leaves open the possibility of new competition for Ambien CR and Lunesta. How does recent FDA action on Indiplon impact development timelines of other late stage insomnia treatments? Will drugs with new mechanisms of action improve sleep maintenence while reducing side effects? Can neurostimulation be used to treat sleep disorders?
|
|
|
Sharon Mates
Chairman and CEO, Intra-Cellular Therapies
David Hale
Executive Chairman, Somaxon
Tim Tasker
EVP Clinical Development, Evotec
Robert Atkinson
President and CEO, Apnex Medical
Ellen Baron
Partner, Oxford Bioscience Partners |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 4:45 - 5:45 |
Traumatic Brain and Spinal Cord Injury
|
|
|
New hope is emerging for treatments of major traumatic injuries to the central nervous system. While venture funding may be scare for such callenging areas, companies are leveraging government support and innovative financing to address these unmet markets. |
|
|
Gary Ascani
President and CEO, Banyan Biomarkers
Vincent Owens
President and CEO, Intelect Medical
Mark Pykett
President and COO, Alseres Pharmaceuticals |
|
|
Tim Surgenor
President and CEO, Cyberkinetics Neurotechnology Systems |
|
|
Session Chair: Dan O'Connell
Managing Director, NeuroVentures Capital |
|
|
|
|
| 5:45 - 7:00 |
Networking and Cocktail Reception |
|
|
Invited Guest Speaker: Representative Patrick Kennedy |
|
|
|
|
|
|
|
|
|
|
Friday May 9, 2008
|
|
|
|
|
|
|
|
| 7:30 - 8:30 |
Continental Breakfast & Registration |
|
|
|
|
|
|
|
|
|
| 8:15 - 9:15 |
Partnering and Licensing in Neurotech Panel |
|
|
|
Big pharma, biotech and medtech are increasingly looking to smaller firms to provide innovative product candidates to fill pipelines. What are current trends in strategic alliances and partnering? Is there a new model for partnerships emerging? Is Big pharma looking to earlier stage product candidates for partnering and inlicensing? Can major medical device companies continue with their high rate of acquisitions?
|
|
|
|
|
|
|
|
Lothar Krinke
Vice President of Research and Business Development, Medtronic Neuromodulation
Xavier Lataste
Global Bus. Dev. and Lic., Head of Neuroscience Search & Evaluation, Novartis
David Schulz
Senior Director, Worldwide Business Development, Pfizer
Jeff Witcher
Neuroscience Evaluation Director, Strategic Planning & BD, AstraZeneca |
|
|
|
|
|
|
|
Moderator: Christine de los Reyes |
|
|
|
Biotech Partnering Solutions |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9:15 - 10:15 |
Next Generation Neuropsychiatry |
|
|
|
|
|
Schizophrenia, anxiety, depression, and other neuropsychiatric illnesses represent a large portion of the neurotech market. What are the most promising next generation treatments? How will devices change the treatment landscape? |
|
|
Luca Santarelli
Global Head of Clinical Research and Exploratory Development, CNS
Hoffmann-La Roche
Jim Schoeneck
President and CEO, BrainCells, Inc.
Uzi Sofer
CEO, Brainsway
Philip Devlin
Executive Vice President and General Manager, Aspect Neuroscience
Session Chair: Manuel Lopez-Figueroa |
|
|
|
Vice President, Bay City Capital
|
|
|
|
|
| 10:15 - 10:45 |
Networking and Refreshment Break |
|
|
|
|
| 10:45 - 11:45 |
Effective Global Clinical Trial Design: Case Studies and Panel Discussion |
|
|
Intelligent clinical trial design is critical to the success of any neurotech venture. The moderator will lead an insider panel in a discussion of specific tactics for improving the design and reducing the cost of trials. Case studies will demonstrate lessons learned in Alzheimer's, depression and more.
|
|
|
Paul Gilbert
CEO, Medavante
Donald deBethizy
President and CEO, Targacept
Michael Kauffman
President and CEO, Epix Pharmaceuticals
John Bowers
CEO, Northstar Neuroscience
Joyce Cramer
President, Epilepsy Therapy Project |
|
|
|
|
| 11:45 - 12:30 |
Pain: Acute, Chronic, and Neuropathic |
|
|
New and innovative pain treatments are reaching the market ranging from abuse resistant opiate forumulations to neurofeedback to noninvasive neuro-stimulation. Companies are working towards treatments for neuropathic pain by targeting entirely new pathways. Hear from a variety of drug and device companies on the leading edge.
Kerrie Brady
CEO, Traxion Therapeutics
Christopher deCharms
President and CEO, Omneuron
Elliot Krames
President, International Neuromodulation Society, Co-Chair National Pain Foundation
Session Chair: T. (Teo) Forcht Dagi
Partner, HLM Venture Partners
|
|
|
|
|
| 12:30 - 2:00 |
Partnering Lunch sponsored by The Neurotechnology Industry Organization |
|
|
|
|
| 2:00 - 3:00 |
Public Policy and Neurotech |
|
|
An overview and participant discussion of current and future congressional, FDA, and CMS initiaves currently active or being pursued to advance neurotech. |
|
|
|
|
|
Zack Lynch
Executive Director, Neurotech Industry Organization
Daniel Ritter
Partner, K&L Gates, NIO Public Policy Counsel
Suzan Onel
Partner, K&L Gates, NIO FDA Policy Counsel
Craig Martin
Managing Director, Feinstein Kean Healthcare |
|
|
|
|
|
|
|
|
|
|
3:00 |
Conference Concludes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
